ARTICLE | Clinical News
MG98: Began Phase II trial
August 27, 2001 7:00 AM UTC
MethylGene Inc., Montreal, Quebec MGI Pharma Inc. (MOGN), Minneapolis, Minn. Product: MG98 Business: Cancer Therapeutic category: Antisense, Gene expression Target: DNA methyltransferase mRNA Descri...